Ivana Krajsová

Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib

Caroline Robert, Bogusława Karaszewska, Jacob Schachter et al. · New England Journal of Medicine · 2014 · 2.7K citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17

Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial

Reinhard Dummer, Paolo A. Ascierto, Helen Gogas et al. · The Lancet Oncology · 2018 · 1K citations · Full text

Medicine, Oncology, Pharmacology +11

Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial

Reinhard Dummer, Paolo A. Ascierto, Helen Gogas et al. · The Lancet Oncology · 2018 · 586 citations

Medicine, Oncology, Pharmacology +11

Vemurafenib in patients with BRAFV600 mutated metastatic melanoma: an open-label, multicentre, safety study

James Larkin, Michele Del Vecchio, Paolo A. Ascierto et al. · The Lancet Oncology · 2014 · 292 citations

Medicine, Oncology, Pharmacology +12

MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial

Brigitte Dréno, John F Thompson, B. Mark Smithers et al. · The Lancet Oncology · 2018 · 198 citations · Full text

Medicine, Immunology, Oncology +14